DUARTE, Calif.--(BUSINESS WIRE)--Already pioneers in the use of immunotherapy, City of Hope researchers are now testing the bold approach to cancer treatment against one of medicine’s biggest challenges: brain cancer. This month, they will launch a clinical trial using patients’ own modified T cells to fight advanced brain tumors.
One of but a few centers in the United States offering human studies in chimeric antigen receptor or CAR–T cell therapy, City of Hope is the only center investigating CAR-T cells in injection form administered directly to brain tumors. In this first-in-humans study, patients with advanced brain tumors will receive injections – directly at the tumor site – of immune cells genetically modified to recognize certain markers on cancer cells.
“The data from our preclinical studies makes us confident that this treatment has the potential to be very powerful and last longer than previous attempts at immunotherapy for brain cancer,” said Benham Badie, M.D., chief of neurosurgery at City of Hope. “This could take the treatment of brain tumors to the next level, and open up a new avenue of treatment to patients who badly need it.”
The safety trial will evaluate the therapy in patients with inoperable glioblastomas and advanced gliomas and in those who have had their tumors surgically removed. The goal is to determine a safe therapeutic dose.
City of Hope has been offering CAR-T cell immunotherapy in clinical trials for several blood cancers. This trial will extend the exciting therapeutic approach to the fight against solid tumors.
T cells are cells in the immune system that recognize threats to the body, then mount an attack. Because cancer can hide from the immune system, CAR-T cell therapy modifies a patient’s T cells to recognize cancer cells. First, a sample of a patient’s T cells are extracted, then genetically modified to recognize receptors on cancer cells.
This City of Hope trial will use a type of T cell known as memory T cells, meaning they replicate in the body and “remember” diseases they’ve fought previously. These memory cells give rise to “soldier” T cells that fight disease. The hope is that the immune system will mount an attack on the existing cancer – then do the same should the cancer recur.
The CAR-T cell laboratory is overseen by Christine Brown, Ph.D., associate director of the T Cell Therapeutics Research Laboratory, and Stephen J. Forman, M.D., Francis & Kathleen McNamara Distinguished Chair in Hematology and Hematopoietic Cell Transplantation.
“CAR-T cell therapy has significant potential to fight not just blood and bone marrow cancers, but a wide range of diseases for which patients need better treatment,” Forman said. “City of Hope is committed to maximizing the potential of this revolutionary therapy for the sake of patients here and around the world.”
The research is being funded through grants from the California Institute of Regenerative Medicine and the Gateway for Cancer Research Foundation.
For more information or to schedule an interview with Badie, contact Media Specialist Denise Heady at 626-218-8803 or by e-mail at firstname.lastname@example.org.
About City of Hope
City of Hope is an independent research and treatment center for cancer, diabetes and other life-threatening diseases. Designated as a comprehensive cancer center, the highest recognition bestowed by the National Cancer Institute, City of Hope is also a founding member of the National Comprehensive Cancer Network, with research and treatment protocols that advance care throughout the nation. City of Hope’s main hospital is located in Duarte, California, just northeast of Los Angeles, with clinics in Antelope Valley and South Pasadena. It is ranked as one of "America's Best Hospitals" in cancer by U.S. News & World Report. Founded in 1913, City of Hope is a pioneer in the fields of bone marrow transplantation and genetics. For more information, visit www.cityofhope.org or follow City of Hope on facebook, twitter, youtube or flickr.